Cheryl Guttman Krader, BS, Pharm

The recently published report from the International Workshop on Meibomian Gland Dysfunction provides an evidence-based review of current knowledge about meibomian gland structure and function in health and disease, offers an idea bank for researchers with an interest in the field, and provides practical guidance to clinicians on the evaluation and management of a very common disorder.

A single intravitreal injection of ocriplasmin is safe, effective, well-tolerated, and is the first pharmacologic treatment for symptomatic vitreomacular adhesion.

On March 16, LENSAR Inc. received 510 (k) clearance from the FDA to market its femtosecond laser system for lens fragmentation in addition to anterior capsulotomy during cataract surgery.

The debate over the need to remove the corneal epithelium when performing corneal collagen crosslinking will continue until long-term data from peer-reviewed studies become available to answer the question of whether a procedure done with the epithelium on results in sufficient crosslinking for long-term arrest of ectasia progression.

A proprietary surgery system brings to laser vision correction surgeons the benefits of expertise in both femtosecond and excimer laser technology.

Use of a commercially available artificial tear product containing propylene glycol as a demulcent and phospholipids in a proprietary emulsion technology reduces tear evaporation for at least 60 minutes post-instillations in patients with aqueous deficient dry eye disease associated with a MGD.

Preoperative cone location appears to affect topographic and visual acuity outcomes of CXL, according to study results.

Results of a study using optical coherence tomography to quantify the tear meniscus provide objective evidence that punctal plugs provide rapid and durable benefits when used from treatment of dry eye.

Findings from analyses of a dataset including more than 250,000 patients provide new information on refractive stability in unoperated eyes and are being applied to establish refractive targets after laser vision correction with the aim of achieving better long-term satisfaction.

Results of a randomized, clinical trial provide evidence to support use of a proprietary oral supplement containing omega-3 fatty acids as a mainstay in the management of dry eye disease.

Implantation of a synthetic intracorneal inlay has been associated with a history of failure when explored as a refractive surgical procedure.

Despite recent advances in understanding of dry eye disease, diagnosis of this common disorder still depends on a multipronged evaluation combination findings from patient history and clinical examination.